Invest In IINN
• Innovative and cost-effective respiratory technology
• Early saturation elevation to minimize the need for mechanical ventilation
• Aims to be administered while patients are awake and breathing spontaneously
• Intended to reduce hospitalization stay and treatment costs
• Total addressable market of $25Bn
• Experienced and committed management team
Behind Our Innovation
Inspira’s core technology has been proven through a series of preclinical trials. The company continues to build its patent portfolio and form collaborations with industry leaders and strategic partner hospitals.
The company’s journey started long before it was formally founded and its vision was born out of necessity.
Immediate relief while the patient is fully awake
Affordable treatment, reduced hospital days & readmissions
Avoids MV risk &
Ease of Use
User-friendly design, extends treatment beyond the ICU